Near human lead antibodies were generated with appropriate potencies and favourable characteristics for development including low aggregation, good stability and good production in CHO based stable cell lines. The development candidate CIT-013 was selected from a set of optimised antibodies. The production of CIT-013 drug substance and drug product has been
conducted by our CMC partner Lonza including cell line generation, cloning, bioreactor scaling, process and formulation development, technical batch and 1000 liter GMP lot production. We started clinical studies in healthy volunteers in August 2021 and plan to start patient studies in 2023.